Leading the Way: The First Guidelines for the Clinical Diagnosis and Treatment of Adult ADHD
Leading the Way The First Guidelines for the Clinical Diagnosis and Treatment of Adult ADHD in the United States Healthcare providers in the United States are not taught how to diagnose and treat ADHD in adults. The absence of clinical practice guidelines for adults has created a significant gap in mental healthcare across the country.…
Read MoreContact Your Senators and Representatives to Request an Increase in Funding for ADHD for the National Center on Birth Defects and Developmental Disabilities
As October marks National ADHD Awareness Month, we stand at a critical juncture to address the public health concern posed by attention-deficit/hyperactivity disorder (ADHD). We urge you to contact your senators to ask them to support the at least 22.6 million individuals in the United States with ADHD, along with their families, by increasing funding…
Read MoreThe Importance of Adult ADHD Guidelines
Featuring Dr. Peter Jensen, MD Download Slides Dr. Peter Jensen, founder of the REACH Institute, is the director of a coalition of organizations that are developing adult ADHD diagnosis and treatment guidelines for use in the United States, a joint effort of CHADD and APSARD. For more information on the development of adult guidelines, read…
Read MoreWhat Is ADHD? How It Impacts Children and Adults
Featuring Max Wiznitzer, MD, Co-chair of CHADD’s Professional Advisory Board Download PDF Learn more about ADHD before the lunch and learn: About ADHD – Overview The Science of ADHD Diagnosing ADHD Treatment of ADHD Frequently Asked Questions Have questions? Email the public policy co-chairs at PublicPolicyLiaison@CHADD.org. The CHADD Public Policy Lunch and Learn is…
Read MoreYou Can Help Protect the Rights of Students with ADHD
Urgent action is needed to encourage the US Department of Education to release updated rules on Section 504 of the Rehabilitation Act of 1973, which provides educational accommodations for children who have ADHD. The process for this release has currently slowed due to a complication at the US Department of Justice, and time is running…
Read MoreTips for Handling the Medication Shortage
ADHD Medication Shortages: What to Know and Do By Andrew Adesman, MD, and Anna Krevskaya, MD Attention, October 2023 In recent years, many new stimulant medications have been approved by the US Food and Drug Administration (FDA) for treatment of ADHD. These new formulations vary in their duration of benefit, and many offer new ways…
Read MoreA Way You Can Address the Medication Shortage
We have heard the frustrations many members of the ADHD community are experiencing when they go to refill their ADHD medications, the disappointment and worry when the pharmacy is unable to fill a prescription because of the ongoing shortage. CHADD’s public policy committee is pursuing all appropriate channels to bring this to the attention of…
Read MoreProtecting Youth Mental Health: The US Surgeon General’s Advisory
The challenges today’s generation of young people face are unprecedented and uniquely hard to navigate. And the effect these challenges have had on their mental health is devastating. Recent national surveys of young people have shown alarming increases in the prevalence of certain mental health challenges. We know that mental health is shaped by many…
Read MoreDeveloping Diagnosis and Treatment of Adult ADHD Guidelines
In 2022, CHADD received funds from a generous donor to sponsor and support the development of national guidelines in the U.S. for the diagnosis and treatment of adult ADHD. This milestone has been achieved due to the sustained efforts of our Public Policy Committee and builds on the committee’s published recommendations emerging from a national…
Read MoreCHADD’s Statement at the Public Meeting on Patient-Focused Drug Development for Stimulant Use Disorder
Posted October 8, 2020 Presentation to the Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the US Food and Drug Administration Public Meeting on Patient-Focused Drug Development for Stimulant Use Disorder Presented by Robert Cattoi, CHADD Chief Executive Officer Children and Adults with Attention-Deficit/Hyperactivity Disorder…
Read MoreUPDATE: CARES Act And Protecting Educational Rights of Students With ADHD
CHADD is pleased to report that Secretary of Education Betsy DeVos will not seek changes to the central tenets of the Individuals with Disabilities Education Act (IDEA) in response to the novel coronavirus pandemic. In her report, the Secretary is “not requesting waiver authority for any of the core tenets of the IDEA or Section…
Read MoreCARES Act And Protecting Educational Rights of Students With ADHD
Read the update to this post. Dear Parents, The Coronavirus Aid, Relief, and Economic Security (CARES) Act, PL 116-136, directs Secretary of Education Betsy DeVos to report back to Congress no later than April 26, 2020, on any waivers needed under the Individuals with Disabilities Education Act (IDEA) and the Rehabilitation Act of 1973 (Section…
Read More